Overview

Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)

Status:
Terminated

Trial end date:
2017-10-17

Target enrollment:

Participant gender:

Summary

This will be multicentre a phase II randomized controlled and open-label trial. It will compare the 6-months objective response (CR+PR) rates obtained with Drug Eluting Bead Trans-Arterial Chemo-Embolization (DEB-TACE) alone versus DEB-TACE followed by Stereotactic Ablative Radiotherapy (SABR) in patients with hepatocarcinoma stage BCLC B. This trial will also include one substudy. This substudy will confront the immuno-histochemical results collected on tumoral biopsies to the biological and imaging (MRI) results. Every patient participating to the trial can also participate to this substudy.

Phase:

Phase 2

Details

Lead Sponsor:

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Collaborators:

Centre Hospitalier Universitaire Dinant Godinne - UCL Namur
Clinique Saint Joseph, Liège
Erasme University Hospital
Jules Bordet Institute
University Hospital of Liege
University of Liege

Treatments:

Chlorotrianisene
Doxorubicin
Liposomal doxorubicin